Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02254785
Title Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
Recruitment Unknown status
Gender male
Phase Phase II
Variant Requirements No
Sponsors British Columbia Cancer Agency
Indications
Therapies
Age Groups: adult
Covered Countries CAN | AUS

Facility Status City State Zip Country Details
Box Hill Hospital Box Hill Victoria 3128 Australia Details
Monash Health-Monash Medical Centre Clayton Victoria 3168 Australia Details
Peter MacCallum Cancer Centre Melbourne Victoria 3000 Australia Details
Tom Baker Cancer Cantre Calgary Alberta T2N 4N2 Canada Details
Cross Cancer Institute Edmonton Alberta T6G 1Z2 Canada Details
BCCA - Kelowna Kelowna British Columbia V1Y 5J3 Canada Details
BCCA- Vancouver Center Vancouver British Columbia V5Z 4E6 Canada Details
CancerCare Manitoba Winnipeg Manitoba R3E 0V9 Canada Details
QEII Health Sciences Centre Halifax Nova Scotia B3H 1V7 Canada Details
Juravinski Cancer Centre Hamilton Ontario L8V 5C2 Canada Details
Durham Regional Cancer Centre (Lakeridge Health) Oshawa Ontario L1G 2B9 Canada Details
The Ottawa Hospital Cancer Centre Ottawa Ontario K1H 8L6 Canada Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2M9 Canada Details
Jewish General Hospital Montreal Quebec H3T 1E2 Canada Details
Saskatoon Cancer Center Saskatoon Saskatchewan 27N 4H4 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field